{
    "clinical_study": {
        "@rank": "82230", 
        "arm_group": [
            {
                "arm_group_label": "MK-3102 25 mg", 
                "arm_group_type": "Experimental", 
                "description": "MK-3102 25 mg, once weekly, for 24 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo to MK-3102, once weekly, for 24 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will examine the safety and efficacy of once-weekly MK-3102 in\n\n      participants 18 to <45 years of age with Type 2 diabetes mellitus and inadequate glycemic\n      control. The study hypothesis is that treatment with MK-3102 compared with placebo provides\n      greater reduction in hemoglobin A1c (A1C) in participants after 24 weeks."
        }, 
        "brief_title": "A Study of the Safety and Efficacy of MK-3102 in \u226518 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028 AM1)", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has type 2 diabetes mellitus\n\n          -  Currently not on an antihyperglycemic agent (AHA) for at least the past 12 weeks and\n             has not been treated with MK-3102 at any time prior to study participation\n\n          -  Participant is one of the following:\n\n               1. Male\n\n               2. Female who is not of reproductive potential\n\n               3. Female of reproductive potential who agrees to remain abstinent from\n                  heterosexual activity or use (or have her partner use) 2 acceptable methods of\n                  contraception to prevent pregnancy during the study and for 21 days after the\n                  last dose of study drug\n\n        Exclusion Criteria:\n\n          -  History of type 1 diabetes mellitus or a history of ketoacidosis\n\n          -  History of hypersensitivity to dipeptidyl-peptidase-4 (DPP-4) inhibitor\n\n          -  Currently participating in or has participated in a clinical trial in the past 12\n             weeks\n\n          -  Is on a weight loss program and not in the maintenance phase; has been on a weight\n             loss medication in the past 6 months; or has undergone bariatric surgery within 12\n             months prior to study participation\n\n          -  Has undergone a surgical procedure within 4 weeks of study participation or has\n             planned major surgery during the study\n\n          -  Is on or likely to require treatment for \u226514 consecutive days or repeated courses of\n             pharmacologic doses of corticosteroids\n\n          -  Is currently being treated for hyperthyroidism or is on thyroid replacement therapy\n             and has not been on a stable dose for at least 6 weeks\n\n          -  Is expecting to undergo hormonal therapy in preparation to donate eggs during the\n             study, including 21 days following the last dose of study drug\n\n          -  History of active liver disease (other than non-alcoholic hepatic steatosis)\n             including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic\n             gallbladder disease\n\n          -  Has human immunodeficiency virus (HIV)\n\n          -  Has had new or worsening coronary heart disease or congestive heart failure within\n             the past 3 months, or has any of the following disorders within the past 3 months:\n\n               1. Acute coronary syndrome\n\n               2. Coronary artery intervention\n\n               3. Stroke or transient ischemic neurological disorder\n\n          -  Has poorly controlled hypertension\n\n          -  History of malignancy \u22645 years prior to study participation, except for basal cell or\n             squamous cell skin cancer or in situ cervical cancer\n\n          -  Has a hematological disorder (such as aplastic anemia, myeloproliferative or\n             myelodysplastic syndromes, thrombocytopenia)\n\n          -  Has a positive urine pregnancy test\n\n          -  Pregnant or breastfeeding, or is expecting to conceive during the study, including 21\n             days following the last dose of study drug\n\n          -  User of recreational or illicit drugs or has had a recent history of drug abuse.\n             Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or\n             engages in binge drinking.\n\n          -  Has donated blood products or has had a phlebotomy (>300 mL) within 8 weeks of study\n             participation, or intends to donate blood products during the study or has received,\n             or is anticipated to receive, blood products within 12 weeks of study participation\n             or during the study\n\n          -  Has a clinically significant electrocardiogram abnormality"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "44 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814748", 
            "org_study_id": "3102-028"
        }, 
        "intervention": [
            {
                "arm_group_label": "MK-3102 25 mg", 
                "description": "MK-3102 25 mg capsule administered orally once weekly", 
                "intervention_name": "MK-3102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Matching placebo to MK-3102 25 mg capsule administered orally once weekly", 
                "intervention_name": "Placebo to MK-3102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-3102 25 mg", 
                    "Placebo"
                ], 
                "description": "Participants exceeding pre-specified glycemic thresholds during the double-blind treatment period will receive rescue therapy with open-label metformin.", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Fortamet\u00ae", 
                    "Glucophage\u00ae", 
                    "Glucophage\u00ae XR", 
                    "Glumetza\u00ae", 
                    "Riomet\u00ae", 
                    "Metgluco\u00ae", 
                    "Glycoran\u00ae"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hypoglycemic Agents", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Diabetes Mellitus", 
            "Diabetes Mellitus, Type 2", 
            "Glucose Metabolism Disorders", 
            "Metabolic Diseases", 
            "Endocrine System Diseases", 
            "Metformin", 
            "Hypoglycemic Agents", 
            "Pharmacologic Actions", 
            "Therapeutic Uses"
        ], 
        "lastchanged_date": "May 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boca Raton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33432"
                    }, 
                    "name": "Call for Information (Investigational Site 0008)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hialeah", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33012"
                    }, 
                    "name": "Call for Information (Investigational Site 0014)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manning", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "29102"
                    }, 
                    "name": "Call for Information (Investigational Site 0003)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dearborn", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48124"
                    }, 
                    "name": "Call for Information (Investigational Site 0007)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greensboro", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27405"
                    }, 
                    "name": "Call for Information (Investigational Site 0016)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77055"
                    }, 
                    "name": "Call for Information (Investigational Site 0010)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77043"
                    }, 
                    "name": "Call for Information (Investigational Site 0011)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eran Gefen", 
                    "phone": "38 (044) 393 74 80"
                }, 
                "facility": {
                    "address": {
                        "city": "Bucharest", 
                        "country": "Romania"
                    }, 
                    "name": "Merck Sharp & Dohme Romania SRL"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Maria Koroleva", 
                    "phone": "7 0959410000"
                }, 
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Merck Sharp & Dohme IDEA, Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eran Gefen", 
                    "phone": "38 (044) 393 74 80"
                }, 
                "facility": {
                    "address": {
                        "city": "Belgrade", 
                        "country": "Serbia"
                    }, 
                    "name": "Merck Sharp & Dohme"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Khanyi Mzolo", 
                    "phone": "27 11 655 3140"
                }, 
                "facility": {
                    "address": {
                        "city": "Midrand", 
                        "country": "South Africa"
                    }, 
                    "name": "MSD (Pty) LTD South Africa"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eran Gefen", 
                    "phone": "38 (044) 393 74 80"
                }, 
                "facility": {
                    "address": {
                        "city": "Kiev", 
                        "country": "Ukraine"
                    }, 
                    "name": "MSD Ukraine LLC"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Romania", 
                "Russian Federation", 
                "Serbia", 
                "South Africa", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-3102 in \u226518 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from Baseline in A1C at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Percentage of Participants Who Experienced at Least One Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 27"
            }, 
            {
                "measure": "Percentage of Participants Who Discontinued from the Study Due to an Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814748"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in 2-hour Post-Meal Glucose (PMG) at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Change in Baseline in Fasting Plasma Glucose (FPG) at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Number of Participants Attaining A1C Glycemic Goals of <7.0% and <6.5%  at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Time to Participant Rescue with Open-label Metformin for Participants Exceeding Pre-specified Glycemic Thresholds", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}